Please login to the form below

Not currently logged in
Email:
Password:

relugolix

This page shows the latest relugolix news and features for those working in and with pharma, biotech and healthcare.

Myovant preps US filing for relugolix in prostate cancer

Myovant preps US filing for relugolix in prostate cancer

Takeda-partnered drug had 97% response rate in advanced prostate cancer. Myovant is locked in a battle with AbbVie for women’s health applications of its GnRH inhibitor relugolix, but a ... The phase 3 HERO trial of Takeda-partnered relugolix has

Latest news

More from news
Approximately 2 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics